

10/511629

DT05 PCT/PTO 18 OCT 2004
#3

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: **Q84193**

Akihiro UMEZAWA, et al.

Appln. No.: **National Stage Entry of PCT/JP03/04812**

Confirmation No.: Not yet assigned

Group Art Unit: Not yet assigned

Filed: **October 18, 2004**

Examiner: Not yet assigned

For: **METHOD OF FORMING PANCREATIC B CELLS FROM MESENCHYMAL CELLS**

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents, other than any U.S. patents and patent publications, is submitted herewith, along with a copy of the corresponding Communication from a Foreign Patent Office.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: National Stage Entry of PCT/JP03/04812

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,


Gordon Kit
Registration No. 30,764

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

GK/lck

Date: October 18, 2004

Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

DT05 ~~Complete & Known~~ PCT/PTO 18 OCT 2004

Application Number

National Stage Entry of
PCT/JP03/04812

Confirmation Number

Not yet assigned

Filing Date

October 18, 2004

First Named Inventor

Akihiro UMEZAWA, et al.

Art Unit

Not yet assigned

Examiner Name

Not yet assigned

Attorney Docket Number

Q84193

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		SILVER, K. et al., ARIP cells as a model for pancreatic beta cell growth and development, Pancreas, 2001, Vol. 22, No. 2, pages 141 to 147	
		RAWDON, B.B. et al., Development of embryonic chick insulin cells in culture: Beneficial effects of serum-free, medium, reised nutrient, and biomatrix, In Vitro Cellular & Developmental Biology Animal, 1997, Vol. 33, No. 10, pages 774 to 782	
		HART, A.W. et al., Attenuation of FGF signaling in mouse beta-cells leads to diabetes, Nature, 2000, Vol. 408, No. 6814, pages 864 to 868	
		NIEUWENHUIZEN, A.G. et al., Progesterone stimulates pancreatic cell proliferation in viro, Eur. J. Endocrinol., 1999, Vol. 140, No. 3, pages 256 to 263	
		FERBER, S. et al., Pancreatic and duodenal homebox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia, Nat. Med., 2000, Vol. 6, No. 5, pages 568 to 572	
		CRISERA, C.A., et al., Expression and role of laminin-1 in mouse pancreatic organogenesis, Diabetes, 2000, Vol. 49, No. 6, pages 936 to 944	
		KERR-CONTE, et al. Ductal cyst formation in collagen-embedded adult human islet preparations. A means to the reproduction of nesidioblastosis in vitro, Diabetes, 1996, Vol. 45, No. 8, pages 1108 to 1114	
		LUMELSKY, N. et al. Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets, Science, 2001, Vol. 292, No. 5520, pages 1389 to 1394	
		SORIA, B. et al. Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice, Diabetes, 2000, Vol. 49, No. 2, pages 157 to 162	
		PITTENGER, M.F. et al., Multilineage potential of adult human mesenchymal stem cells, Science, 1999, Vol. 284, No. 5411, pages 143 to 147	
		RAMIYA, V.K. et al., Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells, Nat. Med., 2000, Vol. 6, No. 3, pages 278 to 282	
		MBALAVIELE, G. et al., Human mesenchymal stem cells promote human osteoclast differentiation from CD34=bone marrow hematopoietic progenitors, Endocrinology, 1999, Vol. 140, No. 8, pages 3736 to 3743	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.